Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.69 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343428 | 0.95 | CYP2C9 (0.77) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL7342966 | 0.92 | CACNA1C (0.62) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL7349734 | 0.92 | CACNA1C (0.67) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL10823927 | 0.92 | CACNA1C (0.62) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL10912838 | 0.91 | CYP2C9 (0.59) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL7433602 | 0.91 | CYP2C9 (0.59) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL10898530 | 0.91 | CACNA1C (0.70) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL10913481 | 0.90 | CACNA1C (0.58) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL10913015 | 0.90 | CYP2C9 (0.58) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL10411085 | 0.90 | CACNA1C (0.64) | CYP2C9CYP1A2CYP3A4CYP2C19CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1700 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| EP-4301370-A1 | COMBINATORY THERAPY FOR PREVENTING, INHIBITING, TREATING, OR REDUCING ANEURYSMS | The Regents of The University of California (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| CN-116600799-A | Pharmaceutical combination for the treatment and/or prophylaxis of diabetes | 银丝佛若有限公司 | 2023-08-15 | — | — | CN | claimed |
| WO-2022187349-A1 | COMBINATORY THERAPY FOR PREVENTING, INHIBITING, TREATING, OR REDUCING ANEURYSMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022074057-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2022-04-14 | — | — | WO | claimed |
| EP-3981401-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR PREVENTION OF DIABETES COMPRISING A CALCIUM CHANNEL BLOCKING AGENT AND AN INCRETIN MIMETIC | InSphero AG (CH) | 2022-04-13 | — | — | EP | claimed |
| WO-1998036733-A2 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER | KAMM MICHAEL ALBERT (GB) | 1998-08-27 | — | — | WO | claimed |
| WO-1995034299-A1 | INHIBITION OF INTRAOPERATIVE MIOSIS/PRODUCTION OF MYDRIASIS BY CALCIUM CHANNEL BLOCKERS | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1995-12-21 | — | — | WO | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-5260321-A | Cardiovascular disorders | SANDOZ LTD. (CH) | 1993-11-09 | — | — | US | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| US-4797404-A | TREATMENT OF MIGRAINES OR HYPERTENSION | SANDOZ LTD. (CH) | 1989-01-10 | — | — | US | claimed |
| US-4466972-A | HYPOTENSIVE, ANTIISCHEMIC, ANTISPASMODIC AGENTS | SANDOZ LTD. (CH) | 1984-08-21 | — | — | US | claimed |
| EP-0000150-B1 | DIHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ AG (CH) | 1981-05-20 | — | — | EP | claimed |
| EP-0000150-A1 | Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them. | SANDOZ AG (CH) | 1979-01-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | CYP2C9 2737/4885CYP1A2 3472/4885CYP3A4 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.